Neuren Pharmaceuticals Limited (AU:NEU) has released an update.
Neuren Pharmaceuticals has announced a share buy-back program worth up to A$50 million, following a lucrative transaction by its licensee Acadia Pharmaceuticals. With strong financial backing from record sales of DAYBUE and proceeds from a voucher sale, Neuren aims to strategically buy back shares over the next year while evaluating market conditions. This move reflects Neuren’s confidence in its financial position and commitment to enhancing shareholder value.
For further insights into AU:NEU stock, check out TipRanks’ Stock Analysis page.
